Compare Micron Technology, Inc. (MU) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Pfizer Inc — how do they compare? Micron Technology, Inc. trades at $1,024.28 (market cap $1.17T), while Pfizer Inc trades at $27.86 (market cap $158.56B). The key difference: Micron Technology, Inc. is far larger — about 7.4× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Pfizer Inc for 158 Days on average.
| MU | PFE | |
|---|---|---|
Market Cap | $1.17T | $158.56B |
Volume | 29,425,906 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $1.21K | $29.02 |
52-Week Low | $181.60 | $23.67 |
Typical Hold Time | 48 Days | 158 Days |
Enterprise Value | $1.13T | $210.06B |
Dividend Yield | 0.06% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,088, up 4.06% with strong bullish momentum, supported by consecutive earnings beats and robust AI-driven memory demand. The stock shows impressive fundamentals with 63.8% net margins and 91.77% ROE, while technical indicators signal bullish moving averages. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility, though growth deceleration concerns linger.
Outlook remains positive with analyst consensus at $1,590 price target (82.85% buy ratings), but risks include cyclical memory pricing, competitive pressures, and potential AI demand normalization. The stock's valuation appears reasonable with P/E of 13.94, supporting continued upside if execution persists.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
